Sarepta (SRPT) Management Firm on Eteplirsen Guidance, Robert Baird Says

Sarepta (Nasdaq: SRPT) management is firm on its guidance for breakthrough designation on eteplirsen, Robert Baird analyst Brian Skorney commented today.

Speaking during an Bloomberg interview, Skorney noted that the firm will be deciding on its strategy within the few months.

Sarepta CEO Chris Garabedian said during its Q1 conference call that the company would make a decision on breakthrough by the end of the second quarter.

Deutsche Bank also said today that there was risk to breakthrough when Prosensa’s Drisapersen comes to market.

Traders aren't taking risks on the designation; from a short interest low of 1.4 percent in July 2012, the number has slowly crept up to 33.5 percent through the middle of June.

Shares of Sarepta are up about 1 percent Wednesday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
• Deutsche Bank Downgrades Tesla (TSLA) to Hold, 'Considerable risk from “going balls to the wall for autonomy”'
• Badger Meter (BMI) PT Raised to $175 at Stifel